

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **Fuse Science, Inc.**

25 N Market St Office 115 Jacksonville, FL 32202

929.209.2028

<https://desks.ai>

[investor@desks.ai](mailto:investor@desks.ai)

4581

## **Quarterly Report**

**For the period ending March 31 2023 (the “Reporting Period”)**

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

80,000,000 as of December 31 2022

250,000,000 as of March 31 2023

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>5</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

---

<sup>5</sup> “Change in Control” shall mean any events resulting in:

(i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Fuse Science, Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada : active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

none

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

none

The address(es) of the issuer's principal executive office:

25 N Market St Office 115 Jacksonville , FL 32202

The address(es) of the issuer's principal place of business:

☒ Check if principal executive office and principal place of business are the same address:

\_\_\_\_\_

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

\_\_\_\_\_

**2) Security Information**

**Transfer Agent**

Name: Equity Stock Transfer

Phone: 212-575-5757

Email: nora@equitystock.com

Address: 237 W 37th St #602 New York, NY 10018

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	<u>DROP</u>			
Exact title and class of securities outstanding:	<u>Common</u>			
CUSIP:	<u>36113J304</u>			
Par or stated value:	<u>0.001</u>			
Total shares authorized:	800,000,000	as of date:	March 31	2023
Total shares outstanding:	250,000,000	as of date:	March 31	2023
Total number of shareholders of record:	<u>73</u>	as of date:	March 31	2023

*All additional class(es) of publicly quoted or traded securities (if any):*

Trading symbol:	_____			
Exact title and class of securities outstanding:	_____			
CUSIP:	_____			
Par or stated value:	_____			
Total shares authorized:	_____	as of date:	_____	
Total shares outstanding:	_____	as of date:	_____	
Total number of shareholders of record:	_____	as of date:	_____	

Trading symbol:	_____			
Exact title and class of securities outstanding:	_____			
CUSIP:	_____			
Par or stated value:	_____			
Total shares authorized:	_____	as of date:	_____	
Total shares outstanding:	_____	as of date:	_____	
Total number of shareholders of record:	_____	as of date:	_____	

**Other classes of authorized or outstanding equity securities:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	<u>SERIES A PREFERRED</u>			
CUSIP (if applicable):	_____			
Par or stated value:	<u>0.00</u>			
Total shares authorized:	1,500,000	as of date:	March 31	2023
Total shares outstanding (if applicable):	1,360,874	as of date:	March 31	2023
Total number of shareholders of record (if applicable):	<u>12</u>	as of date:	March 31	2023

Exact title and class of the security:	<u>SERIES B PREFERRED</u>			
CUSIP (if applicable):	_____			
Par or stated value:	<u>0.00</u>			
Total shares authorized:	3,200,000	as of date:	March 31	2023
Total shares outstanding (if applicable):	3,200,000	as of date:	March 31	2023
Total number of shareholders of record (if applicable):	<u>7</u>	as of date:	March 31	2023

Exact title and class of the security:	<u>SERIES C PREFERRED</u>		
CUSIP (if applicable):	<u>                    </u>		
Par or stated value:	<u>0.00</u>		
Total shares authorized:	<u>3,500,000</u>	as of date: <u>March</u>	31 2023
Total shares outstanding (if applicable):	<u>3,500,000</u>	as of date: <u>March</u>	31 2023
Total number of shareholders of record (if applicable):	<u>7</u>	as of date: <u>March</u>	31 2023

Exact title and class of the security:	<u>SERIES D PREFERRED</u>		
CUSIP (if applicable):	<u>                    </u>		
Par or stated value:	<u>0.00</u>		
Total shares authorized:	<u>100,000</u>	as of date: <u>March</u>	31 2023
Total shares outstanding (if applicable):	<u>100,000</u>	as of date: <u>March</u>	31 2023
Total number of shareholders of record (if applicable):	<u>1</u>	as of date: <u>March</u>	31 2023



### **Security Description:**

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

none

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series D include super voting rights and are solely owned by Esau Delke / President

3. Describe any other material rights of common or preferred stockholders.

none

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

none

### **3) Issuance History**

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### **A. Changes to the Number of Outstanding Shares**

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☒ Yes: ☐ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:  Opening Balance Date 9 / 30 / 2021 Common: 80,000,000 Preferred:			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per	Were the shares issued at a discount to market price at	Individual/ Entity Shares were issued to.  *You must disclose the	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

				share) at Issuance	the time of issuance? (Yes/No)	control person(s) for any entities listed.	Services Provided		
3 / 6 / 2023	new issuance	145,000,000	common	\$0.001	yes	Esau David Delke	employee compensation	Restricted	Rule-144
2 / 14 / 2023	new issuance	10,000,000	common	\$0.001	yes	MIROSLAV ZECEVIC	professional services,	Restricted	Rule-144
2 / 14 / 2023	new issuance	10,000,000	common	\$0.001	yes	ZORAN CVETOJEVIC	professional services,	Restricted	Rule-144
3 / 6 / 2023	new issuance	5,000,000	common	\$0.001	yes	BRANDON DEAN	Settlement of Agreement with Prior Management	Restricted	Rule-144
Shares Outstanding on Date of This Report:									
Ending Balance:									
Date 5 / 15 / 2023									
Common: 250,000,000									
Preferred: _____									

The purpose of this section is to provide a clear description of the issuer's current operations.  
(Please ensure that these descriptions are updated on the Company's Profile on [www.otcmarkets.com](http://www.otcmarkets.com)).

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")  
Desk AI a cloud based customer engagement software platform focused on development and distribution of AI avatars that produce content and perform tasks with focus on computer vision and generative AI not limited to customer service and remote assistance, including live video support for businesses in the private and public sector.
- B. List any subsidiaries, parent company, or affiliated companies.  
none
- C. Describe the issuers' principal products or services. Desk AI.

## 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company leases an office at 25 N Market st, Jacksonville FL 32202 for \$957 USD per month on a year lease.

## 6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuers securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Esau Delke	Ceo / Director	Jacksonville / FL	100,000	Series D Preferred	100%	
Esau Delke	Ceo / Director	Jacksonville / FL	145,000,000	common	58%	

_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

**7) Legal/Disciplinary History**

- A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:
1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);  
  
\_\_\_\_\_no\_\_\_\_\_
  2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;  
  
\_\_\_\_\_no\_\_\_\_\_
  3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or  
  
\_\_\_\_\_no\_\_\_\_\_
  4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.  
  
\_\_\_\_\_no\_\_\_\_\_
- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.  
  
\_\_\_\_\_none\_\_\_\_\_

**8) Third Party Service Providers**

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Don Keer  
Address 1: 3663 Greenwood Circle Chalfont, PA 18914  
Address 2: \_\_\_\_\_  
Phone: 215-962-9378  
Email: \_\_\_\_\_

Accountant or Auditor

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

*All other means of Investor Communication:*

Twitter: @daviddelke @desks\_ai  
Discord: \_\_\_\_\_  
LinkedIn: \_\_\_\_\_  
Facebook: \_\_\_\_\_  
[Other ]: \_\_\_\_\_

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

**9) Financial Statements**

A. The following financial statements were prepared in accordance with:

- ☐ IFRS  
☒ U.S. GAAP

B. The following financial statements were prepared by (name of individual)<sup>6</sup>:

Name: Esau Delke  
Title: CEO / Director  
Relationship to Issuer: CEO / Director

Describe the qualifications of the person or persons who prepared the financial statements: CEO / Director

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

## 10) Issuer Certification

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Esau Delke certify that:

1. I have reviewed this Disclosure Statement for Fuse Science, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

\_\_\_\_\_ 05-15-2023

\_\_\_\_\_ *Esau David Delke* CEO / Director

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, Esau Delke certify that:

<sup>6</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

1. I have reviewed this Disclosure Statement for Fuse Science, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

\_\_\_\_\_ 05-15-2023

\_\_\_\_\_ *Esau David Delke* CEO / Director

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**Fuse Science, Inc.**  
**Notes to the Financial Statements**  
**For the quarter ended March 31 2023**

**(1) LEGAL STATUS AND OPERATIONS**

Fuse Science, Inc. ("the Company") was incorporated in Nevada on September 21, 1988.

The Company, operates the cloud customer engagement software platform Desk AI.

**(2) BASIS OF PREPARATION**

**2.1 Statement of compliance**

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") on a going concern.

**2.2 Accounting Convention**

These financial statements have been prepared on the basis of 'historical cost convention using accrual basis of accounting except as otherwise stated in the respective accounting policies notes.

**2.3 Going concern**

The Company has no concerns.

**2.4 Critical accounting estimates and judgements**

The preparation of financial statements in conformity with the approved accounting standards require management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments

about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates



reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of the revision and future periods.

The areas involving higher degree of judgment and complexity, or areas where assumptions and estimates made by the management are significant to the financial statements are as follows:

- i) Provision for income tax (note - 3.1)
- iii) Stock based compensation (note - 3.12)

### **3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### **3.1 Income tax**

The tax expense for the year comprises of income tax, and is recognized in the statement of earnings. The income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred income tax is accounted for using the balance sheet liability method in respect of all temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred income tax liabilities are recognised for all taxable temporary differences and deferred income tax assets are recognised to the extent that it is probable that taxable profits will be available against which the deductible temporary differences and unused tax losses can be utilized. Deferred income tax is calculated at the rates that are expected to apply to the period when the differences are expected to be reversed.

#### **3.2 Accounts payable**

Liabilities for trade and other amounts payable are carried at cost, which is the fair value of the consideration to be paid in future for goods and services received, whether or not billed to the Company.

#### **3.3 Provisions**

A provision is recognized in the financial statements when the Company has a legal or constructive obligation as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of obligation.

#### **3.4 Accounts Receivable**

Accounts receivable are non-interest bearing obligations due under normal course of business. The management reviews accounts receivable on a monthly basis to determine if any receivables will be potentially uncollectible. Historical bad debts and current economic trends are used in evaluating the allowance for doubtful accounts. The Company includes any accounts receivable balances that are determined to be uncollectible in its overall allowance for doubtful accounts. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on the information available, the Company believes its allowance for doubtful accounts as of period ended is adequate.

### **3.5 Contingent liabilities**

A contingent liability is disclosed when the Company has a possible obligation as a result of past events, the existence of which will be confirmed only by the occurrence or non-occurrence, of one or more uncertain future events, not wholly within the control of the Company; or when the Company has a present legal or constructive obligation, that arises from past events, but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, or the amount of the obligation cannot be measured with sufficient reliability.

### **3.6 Financial liabilities**

Financial liabilities are recognized when the Company becomes party to the contractual provision of the instruments and the Company loses control of the contractual right that comprise the financial liability when the obligation specified in the contract is discharged, cancelled or expired. The Company classifies its financial liabilities in two categories: at fair value through profit or loss and financial liabilities measured at amortized cost. The classification depends on the purpose for which the financial liabilities were incurred. Management determines the classification of its financial liabilities at initial recognition.

#### **(a) *Financial liabilities at fair value through profit or loss***

Financial liabilities at fair value through profit or loss are financial liabilities held for trading. A financial liability is classified in this category if incurred principally for the purpose of trading or payment in the short-term. Derivatives (if any) are also categorized as held for trading unless they are designated as hedges.

#### **(b) *Financial liabilities measured at amortized cost***

These are non-derivative financial liabilities with fixed or determinable payments that are not quoted in an active market. These are recognized initially at fair value, net of transaction costs incurred and are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the profit and loss account.

### **3.7 Cash and cash equivalents**

Cash and cash equivalents include cash in hand and deposits held at call with banks. For the purpose of the statement of cash flows, cash and cash equivalents bank balances and short term highly liquid investments subject to an insignificant risk of changes in value and with maturities of less than three months.

### **3.8 Revenue recognition**

Revenue is recognised to the extent it is probable that the economic benefits will flow to the Company and the revenue can be measured reliably. Revenue is measured at the fair value of the consideration received or receivable for goods sold or services rendered, net of discounts and sales tax and is recognised when significant risks and rewards are transferred.

### **3.9 Functional and presentation currency**

Items included in the financial statements are measured using the currency of the primary economic environment in which the Company operates. The financial statements are presented in US (Dollars) which is the Company's presentation currency. All financial information presented in US Dollars has been rounded to the nearest dollar unless otherwise stated.

### **3.10 Foreign currency transactions**

Foreign currency transactions are translated into the functional currency using the exchange rate prevailing on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into functional currency using the exchange rate prevailing at the statement

currencies are translated into functional currency using the exchange rate prevailing at the statement of financial position date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates are recognized in the statement of operations.

### **3.11 Contingencies**

The assessment of the contingencies inherently involves the exercise of significant judgment as the outcome of the future events cannot be predicted with certainty. The Company, based on the availability of the latest information, estimates the value of contingent assets and liabilities, which may differ on the occurrence / non-occurrence of the uncertain future event(s).

### **3.12 Stock based compensation**

The Company recognizes compensation expense for stock-based compensation in accordance with generally accepted accounting principles. For employee stock-based awards, fair value of the award on the date of grant is calculated using the Black-Scholes method and the quoted price of the Company's common stock for stock options and unrestricted shares respectively;

The Company recognizes expense over the service period for awards expected to vest.

In case of non-employee stock-based awards, fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient's performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.

The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted.

Fuse Science, Inc.  
Balance Sheet  
As at March 31 2023 (unaudited)

	Notes	As at December 31 2022 (Unaudited)(\$)		As at March 31 2023 (Unaudited)(\$)	
<b>ASSETS</b>					
<b>Current Assets</b>					
Cash and cash equivalents	(4)	200.65		(388.00)	
Due from related parties	(5)	- 0		0	
Investment in marketable securities	6	0	-	0	
Prepaid expenses	7	0-		0-	
Other assets		-		0-	-
<b>Total Current Assets</b>		<b>200.65</b>		<b>(388.00)</b>	<b>-</b>
Intellectual property, net	- 8	0-		0-	
Property, plant and equipment, net	- 9	0-		0-	
<b>Total Assets</b>	<b>-</b>	<b>-</b>		<b>-</b>	
		200.65		(388.00)	
<b>EQUITY &amp; LIABILITIES</b>					
<b>Current Liabilities</b>					
Accounts payable	10	-		0	
Notes payable - related party		-		0	
Accrued expenses	11	-		0	
<b>Total Current Liabilities</b>		<b>-</b>		<b>0</b>	
Derivative liabilities	12	-		0-	
<b>Total Liabilities</b>		<b>-</b>		<b>0</b>	
<b>SHAREHOLDER'S EQUITY</b>					
Preferred Stock - (\$.001 par value, 10,000,000 shares authorized)		-		-	
Series A - Convertible Preferred Stock - (\$.001 par value, 1,500,000 shares designated)		-		-	
Series B - Convertible Preferred Stock - (\$.001 par value, 3,200,000 shares designated)		-		-	
Series C - Convertible Preferred Stock - (\$.001 par value, 3,500,000 shares designated)		-		-	
Common stock (\$.0001 par value, 800,000,000 shares authorized)		-		-	
Additional paid in capital		-		-	
Accumulated deficit		-		-	
<b>Total Shareholders' Equity</b>		<b>-</b>		<b>-</b>	
Non-controlling interest		-		-	
<b>Total Liabilities and Equity</b>		<b>-</b>		<b>-</b>	
		0		0	
		-		-	

Fuse Science, Inc.  
Consolidated Statement of  
Operations As at March 31  
2023 (unaudited)

Notes	For the quarter ended December 31, 2022	For the quarter ended March 31, 2023
	---- Amount in \$ ----	
	14,860	20,039
SALES	0	0
COST OF SALES		
GROSS PROFIT	14,860	20,039
OPERATING EXPENSES		
Sales and marketing expense	4,659.35	4,500
General and administrative expense	10,000	15,927
Research and development		0 -
Loss on retirement of assets	0 -	0 -
TOTAL OPERATING EXPENSES	14,659.35	20,427
OPERATING PROFIT / (LOSS)		(388.00)
OTHER INCOME / (EXPENSE)	0	0
Interest expense	0 -	0 -
Expense on issuance of warrant derivative liability	0 -	0 -
Change in fair value of derivative liabilities	0 -	0 -
Expense on inducement of warrant exchange	0 -	0 -
Gain on debt extinguishment	0 -	0 -
PROFIT / (LOSS) BEFORE TAX	200.65	(388.00)
Taxes		
NET PROFIT / (LOSS)	-	-
Net loss attributable to the non-controlling interest	-	-
Net loss attributable to common Shareholders	-	-

Fuse Science, Inc.  
Statement of cashflows  
As at March 31 2023 (unaudited)

Cash flow from operating activities	December 31 2022	March 31 2023
(Loss) / profit before income tax	200.65	(388.00)
Adjustment for non cash charges and other items	-	-
Changes in operating assets	-	-
Decrease / (increase) in account receivable	-	-
Decrease / (increase) in inventory	-	-
Decrease / (increase) in due from related party	-	-
Decrease / (increase) in prepaid expenses	-	-
Decrease / (increase) in other assets	-	-
(Decrease) / increase in accounts payable	-	-
(Decrease) / increase in accrued expenses	-	-
Cash flow from operating activities	200.65	(388.00)
	0	0
Cash flow from investing activities		
Additions / disposal in intellectual properties	-	-
Additions in property, plant and equipment	-	-
Additions in investments	-	-
Cash flow from / (used) in investing activities	-	-
Cash flow from financing activities		
Borrowings during / (repaid) the year	-	-
Proceeds from warrant exercise	-	-
Issuance of share capital	-	-
Cash flow from financing activities	-	-
Increase/(decrease) in cash and cash equivalents	200.65	(388.00)
Cash and cash equivalents at beginning of the y quarter	0	0
Cash and cash equivalents at end of the quarter	200.65	(388.00)
	-	-



Fuse Science, Inc. Statement  
of Shareholders' Equity As at  
March 31 2023 (unaudited)

	Preferred Stock		Series A - Preferred Stock		Series B - Preferred Stock		Series C - Preferred Stock		Common Stock		Additonal Paid in capital	Accumulated Profit / (Deficit)	Non-controlling interest	Total
	Shares	Par	Shares	Par	Shares	Par	Shares	Par	Shares	Par				
As at December 31 2022	-	-	1,500,000	-	3,200,000	-	3,500,000	-	80,000,000	-	-	-	-	-
(unaudited) Profit / (loss) for the												-	-	-
period	-	-	1,500,000	-	3,200,000	-	3,500,000	-	80,000,000	-	-	-	-	-
As at March 31 2023	-	-	1,500,000	-	3,200,000	-	3,500,000	-	80,000,000	-	-	-	-	-
(unaudited)	-	-	1,500,000	-	3,200,000	-	3,500,000	-	80,000,000	-	-	-	-	-

4    **Cash and cash equivalents**

This represent cash in hand and cash deposited in bank accounts (current) by the Company.

Amount in  
\$ (388.00)

5    **Due from related parties**

Opening balance	-
Net movement during the period	-
Closing balance	-

6    **Investment in marketable securities**

Opening balance	-
Net movement during the period	-
Closing balance	-

7    **Prepaid expenses**

Opening balance	-
Net movement during the period	-
Closing balance	-

8    **Intellectual property, net**

Opening balance	-
Net movement during the period	-
Closing balance	-

9    **Property, plant and equipment, net**

Land and building (hotel)	-
---------------------------	---

10   **Accounts payable**

Opening balance	-
Net movement in liabilities during the period	-
Closing balance	-

11   **Notes payable - related party**

Opening balance	-
Net movement in liabilities during the period	-
Closing balance	-

11   **Accrued expenses**

Opening balance	-
Net movement in liabilities during the period	-
Closing balance	-

12   **Derivative liabilities**

Opening balance	-
Net movement in liabilities during the period	-
Closing balance	-

13   **Contingencies and Commitments**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As at the end of current reporting period, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of operations and there are no proceedings in which any directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to the Company's interest.

Chief Executive

*Esau Delke*

Director

*Esau Delke*